Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 4/20 | 0.57 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.57 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.57 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.57 |
| ▸ | TSHR | P16473 | 2/20 | 0.56 |
| ▸ | NPC1 | O15118 | 1/20 | 0.55 |
| ▸ | RAB9A | P51151 | 1/20 | 0.55 |
| ▸ | ATM | Q13315 | 1/20 | 0.55 |
| ▸ | MEN1 | O00255 | 2/20 | 0.52 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.52 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.48 |
| ▸ | THRA | P10827 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11250764 | 0.88 | GAA (0.60) | MAPTALDH1A1KDM4ETDP1NPC1 | |
| SCHEMBL25920577 | 0.83 | MAPT (0.62) | MAPTALDH1A1KDM4ETDP1TSHR | |
| SCHEMBL11246229 | 0.82 | MAPT (0.55) | MAPTALDH1A1KDM4ETDP1NPC1 | |
| SCHEMBL7338580 | 0.82 | PTPRF (0.69) | MAPTALDH1A1KDM4ETDP1TSHR | |
| SCHEMBL30301289 | 0.81 | CYP1A2 (0.65) | MAPTALDH1A1KDM4ETDP1TSHR | |
| SCHEMBL11226242 | 0.80 | MAPT (0.58) | MAPTALDH1A1KDM4ETDP1MEN1 | |
| SCHEMBL27502394 | 0.79 | HIF1A (0.63) | MAPTALDH1A1KDM4ERAB9AMEN1 | |
| SCHEMBL5089392 | 0.79 | CAMKK2 (0.51) | MAPTALDH1A1KDM4ETSHRNPC1 | |
| SCHEMBL13812984 | 0.78 | MAPT (0.62) | MAPTALDH1A1KDM4ETDP1NPC1 | |
| SCHEMBL4956305 | 0.78 | PTPRF (0.68) | MAPTALDH1A1KDM4ETDP1MEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20050182040-A1 | Benzamide derivatives | DAINIPPON SUMITOMO PHARMA CO., LTD. (JP) | 2005-08-18 | — | — | US | disclosed |
| EP-1500643-A1 | BENZAMIDE DERIVATIVES | SUMITOMO PHARMACEUTICALS COMPANY, LIMITED (JP) | 2005-01-26 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050182040-A1 | Benzamide derivatives | ROCK1, ROCK2, NHERF1 | MAPT 4237/4885ALDH1A1 2454/4885KDM4E 2017/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.